Skip to Content

Qutenza Approval History

  • FDA approved: Yes (First approved November 16th, 2009)
  • Brand name: Qutenza
  • Generic name: capsaicin
  • Dosage form: Transdermal Patch
  • Previous name: NGX-4010
  • Company: NeurogesX, Inc.
  • Treatment for: Postherpetic Neuralgia

Qutenza, formerly NGX-4010, is a capsaicin transdermal patch for the management of pain due to postherpetic neuralgia.

Development History and FDA Approval Process for Qutenza

Nov 16, 2009Approval NeurogesX Receives FDA Approval of Qutenza (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Aug  6, 2009NeurogesX Announces New PDUFA Date for Qutenza New Drug Application
Jun 10, 2009NeurogesX Provides U.S. Regulatory Update for Qutenza
Dec 19, 2008NeurogesX Announces FDA Acceptance to Review New Drug Application for NGX-4010 to Treat Post-Herpetic Neuralgia
Oct 22, 2008NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.